NCT00458822View on ClinicalTrials.gov

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

bortezomib

Given IV

DRUG

dexamethasone

Given orally

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00458822 - Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis | Biotech Hunter | Biotech Hunter